Hospital-Community-Family-Care Management Platform for Chronic Heart Failure

Chronic Heart Failure Clinical Trial

— HCF-CMP-CHF  

Official title:

Remote Prevention and Treatment Based on Community Under the Guidance of Regional Central Hospital for Patients With Chronic Heart Failure

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02029287
• Other study ID #: BL2013022
• Status: Recruiting
• Phase: N/A
• Start date: December 2013
• Est. completion date: December 2020

Study information

• Verified date: July 2019
• Source: Northern Jiangsu Province People's Hospital
• Contact: Xiang Gu, Doctor
• Phone: +86 0514 87373366
• Email: sbyygx189[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the Hospital-Community-Family-Care Management Platform for Chronic Heart Failure reduces the mortality, readmission rates and costs of the subjects with CHF.

Description:

(1) Indication: Chronic Heart Failure. (2) Objectives: Primary objective is to evaluate the efficacy of the Hospital-Community-Family-Care Management Platform online compared with the regular clinic follow up in subjects with CHF (I-IV class by NYHA, of which class IV without strict bed rest).Secondary objectives is to assess the safety of the Management Platform online in subjects with CHF. (3) Study design: Prospective, randomized, controlled study with two follow up management groups: 1) the Hospital-Community-Family-Care Management Follow up Online; 2) the regular monthly clinic follow up. Study population: Totally 1000 male and female subjects with CHF (I-IV functional class according to NYHA classification). (4) Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing. (5) Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. (6) Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources. (7) Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. (8) Duration of follow up: The total follow-up time shall be at least 12 months. (9) Safety Assessment: Safety of the study will be evaluated by the following assessments: 1) Subject and object examinations (during the follow up period and extending up to 2 week after the end of the study) consisting of a subject interview (including direct questioning about adverse events), physical examination, assessment of body weight, Electrocardiogram (ECG) and echocardiogram (UCG), Left ventricular ejection fraction (LVEF), assessed by echocardiography, The N-terminal prohormone of brain natriuretic peptide (NT-proBNP), a peptide hormone whose plasma concentration is inversely related to the severity of HF, NYHA functional status, assessed by subject interview, 6-minute walk distance (6MWD), Quality of life (QoL), assessed by the Minnesota Living with Heart Failure questionnaire (MLHFQ), a validated questionnaire assessing QoL in subjects with heart failure. 2) Evaluation of clinically relevant safety laboratory parameters, such as complete blood count, serum creatinine, electrolytes, and liver enzymes. Any Adverse Events (AE) or Serious Adverse Events (SAE) and its potential causal relationship with the study will be recorded and evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2020
• Est. primary completion date: August 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:Inclusion Criteria:to be considered eligible to participate in this study, a subject must meet the inclusion criteria listed below at the time of screening and randomization:

1. Male and female are aged 18 years old or over.

2. History of CHF for =3 months with NYHA functional class I-IV, of which class IV without strict bed rest.

3. Left ventricular ejection fraction (LVEF) =45% as assessed by echocardiogram. However, LVEF can be above 45% for patients with cardiac insufficiency caused by atrial fibrillation, valvular heart disease, hypertrophic cardiomyopathy and et al;

4. Treatment of CHF with stable and optimal pharmacological therapy according to Chinese guidelines for treatment of CHF. In general, optimal treatment will include a beta-blocker and an ACE inhibitor and/or an angiotensin receptor blocker, unless not tolerated. Medical therapy is defined as stable, if the subject has not started a new CHF drug class and the dose of drugs taken have not been changed during the 3 months prior to screening and randomization.

5. Ability to understand the requirements of the study and willingness to provide written informed consent (IC), and agreement to abide by the study restrictions and return for the required assessments.

6. Subjects are located in our coverage of the remote monitoring system.

Exclusion Criteria:To be eligible for entry into the study, the subject must not meet any of the exclusion criteria listed below at screening and randomization:

1. Some secondary cardiomyopathy: hyperthyroid heart disease and anemic heart disease, and et al;

2. A history of malignancy, and life expectancy is less than 1 year;

3. Severe primary hepatic and renal insufficiency (alanine aminotransferase=100 u/L, serum creatinine >3.0mg/dL, serum albumin <2.5g/L);

4. Refusal to participate;

5. Unable to visit outpatient clinics periodically;

6. Ambulatory population;

7. Patients were considered inappropriate to participate by researchers.

Related Conditions & MeSH terms

• Chronic Heart Failure
• Heart Failure

Intervention

Other:
• Hospital-Community-Family-Care Management Platform Online
Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
• Subjects with CHF via conventional clinic visit according to the latest relevant guidelines
Subjects with CHF via conventional clinic visit according to the latest relevant guidelines

Locations

Country	Name	City	State
China	Department of cardiovascular medicine,Northern Jiangsu Hospital	Yangzhou	Jiangsu

Sponsors (3)

Lead Sponsor	Collaborator
Xiang Gu	Science and Technology Department of Jiangsu Province, Yangzhou Municipal Health Bureau

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	heart failure worsening	Number of subjects requiring drug or dose changes to intensify concomitant therapy due to worsening of heart failure (HF).	one year
Other	Hospitalization rate	Hospitalization rate associated with heart failure	one year
Other	Average hospitalization time	Average hospitalization time associated with heart failure	one year
Other	Costs of medications	Costs of medications associated with heart failure	one year
Other	Usability of the HCF intervention for patients	it was assessed based on the Perceived Health Web Site Usability Questionnaire (PHWSUQ-12)	4 months
Other	Changes of self-management	Lifestyle and health behaviors of participants were collected by interview	4 months
Other	Engagement of the intervention	It was assessed objectively via daily Web portal log-ins and use of the mobile APP	4 months
Other	Participants perceptions of intervention components	During the interview, qualitative method was used to examine participants perceptions of intervention components	4 months
Primary	all cause mortality	Number of subjects with all cause death	one year
Secondary	Heart failure morbidity	number of subjects with heart failure - related visits	one year